Cutting the cost of South African antiretroviral therapy using newer, safer drugs

  • W D F Venter
  • B Kaiser
  • B Kaiser
  • F Conradie
  • G B Gomez
  • P Clayden
  • M Matsolo
  • C Amole
  • L Rutter
  • F Abdullah
  • E J Abrams
  • C P Casas
  • M Barnhart
  • A Pillay
  • A Pozniak
  • A Hill
  • L Fairlie
  • M Boffito
  • M Moorhouse
  • M Chersich
  • C Serenata
  • J Quevedo
  • G Loots


Antiretrovirals are a significant cost driver for HIV programmes. Current first-line regimens have performed well in real-life programmes, but have a low barrier to virological resistance and still carry toxicity that limits adherence. New drug developments may mean that we have access to safer, more robust and cheaper regimens, but only if the appropriate clinical trials are conducted. We briefly discuss these trials, and demonstrate the large cost savings to the South African HIV programme if these are successful.


Journal Identifiers

eISSN: 0256-95749
print ISSN: 2078-5135